Evogene Reports Q1 2026 Financial Results and Strategic Expansion of AI Collaborations

Evogene Ltd. (NASDAQ: EVGN) reported financial results for the first quarter ended March 31, 2026. The company reported revenues of approximately $0.3 million, a significant decrease from $2.3 million in Q1 2025, primarily due to lower seed sales from its Casterra subsidiary. Net loss for the quarter widened to $5.9 million, compared to $3.0 million in the prior year, impacted by a $3.8 million financing expense related to a February 2026 warrant inducement transaction. Evogene held $13.1 million in consolidated cash as of March 31, 2026. Strategically, Evogene is transitioning to focus on its ChemPass AI™ platform for small-molecule discovery. During Q1, the company announced a second collaboration with Google Cloud and three new pharmaceutical collaborations with Systasy Biosciences, Queensland University of Technology, and Unravel Biosciences. In the agricultural sector, subsidiary AgPlenus and Bayer discontinued their herbicide development project as the target protein did not meet criteria. Additionally, non-core subsidiaries Lavie Bio and Biomica received court approvals for dividend distributions, with Evogene entitled to approximately $2.9 million and $1.35 million, respectively, expected in Q2 2026.